Premium
Immunogenicity and reactogenicity of DTPa‐HBV‐IPV/Hib vaccine as primary and booster vaccination in low‐birth‐weight premature infants
Author(s) -
Vázquez Liliana,
Garcia Fabiana,
Rüttimann Ricardo,
Coconier Gustavo,
Jacquet JeanneMarie,
Schuerman Lode
Publication year - 2008
Publication title -
acta pædiatrica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.772
H-Index - 115
eISSN - 1651-2227
pISSN - 0803-5253
DOI - 10.1111/j.1651-2227.2008.00884.x
Subject(s) - medicine , reactogenicity , vaccination , booster dose , pediatrics , booster (rocketry) , low birth weight , immunization , immunogenicity , hepatitis b , hepatitis b vaccine , birth weight , immunology , antigen , hepatitis b virus , pregnancy , hbsag , virus , physics , astronomy , biology , genetics
Aim: To assess suitability of a combined DTPa‐HBV‐IPV/Hib vaccine ( Infanrix hexa ™) for immunization of low‐birth‐weight (<2.0 kg) preterm infants, with particular focus on the hepatitis B response. Methods: Open‐label study in 170 preterm infants receiving primary vaccination at 2, 4 and 6 months of age and booster vaccination at 18–24 months. Enrolment and analysis were stratified in two groups: infants with birth weight between 1.5 kg and 2.0 kg (low birth weight: LBW), infants with BW <1.5 kg (very low birth weight: VLBW). Results: One month after the three dose primary vaccination, 93.7% and 94.9% of infants in VLBW and LBW groups, respectively, had anti‐HBs antibody concentrations ≥ 10 mIU/mL. High seroprotection and response rates (92.4–100%) to all vaccine antigens were observed. Those were reinforced (>98%) by booster vaccination for all antigens except for HBs in VLBW children: only 88.7% of those had anti‐HBs antibody concentrations ≥ 10 mIU/mL, compared with 96.5% of LBW children (difference statistically not significant). The vaccine was well tolerated in both groups of infants. Conclusion: Preterm infants will benefit by the administration of a primary and booster vaccination with DTPa‐HBV‐IPV/Hib vaccine.